ATE275402T1 - Arzneimittel zur behandlung von darmverstopfung und reizkolon - Google Patents

Arzneimittel zur behandlung von darmverstopfung und reizkolon

Info

Publication number
ATE275402T1
ATE275402T1 AT00971617T AT00971617T ATE275402T1 AT E275402 T1 ATE275402 T1 AT E275402T1 AT 00971617 T AT00971617 T AT 00971617T AT 00971617 T AT00971617 T AT 00971617T AT E275402 T1 ATE275402 T1 AT E275402T1
Authority
AT
Austria
Prior art keywords
intestinal
constitution
treatment
medicinal products
irritable colon
Prior art date
Application number
AT00971617T
Other languages
English (en)
Inventor
John Rhodes
Brian Kenneth Evans
Original Assignee
John Rhodes
Brian Kenneth Evans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9925872A external-priority patent/GB9925872D0/en
Priority claimed from GB9928314A external-priority patent/GB9928314D0/en
Application filed by John Rhodes, Brian Kenneth Evans filed Critical John Rhodes
Application granted granted Critical
Publication of ATE275402T1 publication Critical patent/ATE275402T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
AT00971617T 1999-11-01 2000-10-30 Arzneimittel zur behandlung von darmverstopfung und reizkolon ATE275402T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9925872A GB9925872D0 (en) 1999-11-01 1999-11-01 Composition for relief of constipation
GB9928314A GB9928314D0 (en) 1999-11-30 1999-11-30 Composition for the treatment of irritable bowel syndrome
PCT/GB2000/004167 WO2001032180A2 (en) 1999-11-01 2000-10-30 Composition for treatment of constipation and irritable bowel syndrome

Publications (1)

Publication Number Publication Date
ATE275402T1 true ATE275402T1 (de) 2004-09-15

Family

ID=26316047

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00971617T ATE275402T1 (de) 1999-11-01 2000-10-30 Arzneimittel zur behandlung von darmverstopfung und reizkolon

Country Status (14)

Country Link
US (1) US6734188B1 (de)
EP (1) EP1225897B1 (de)
JP (1) JP2003513045A (de)
AT (1) ATE275402T1 (de)
AU (1) AU776567B2 (de)
CA (1) CA2389650C (de)
CZ (1) CZ299726B6 (de)
DE (1) DE60013630T2 (de)
DK (1) DK1225897T3 (de)
ES (1) ES2226933T3 (de)
HK (1) HK1048595A1 (de)
IL (2) IL149378A0 (de)
PT (1) PT1225897E (de)
WO (1) WO2001032180A2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1685839T1 (sl) 1997-12-22 2013-08-30 Euro-Celtique S.A. Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista
ATE275402T1 (de) 1999-11-01 2004-09-15 John Rhodes Arzneimittel zur behandlung von darmverstopfung und reizkolon
EP2092936B1 (de) 2000-02-08 2013-03-20 Euro-Celtique S.A. Missbrauchssichere orale Opioidagonisten-Formulierungen
WO2002092060A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US7943173B2 (en) 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
IL160222A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
ES2546010T3 (es) 2002-04-05 2015-09-17 Euro-Celtique S.A. Preparación farmacéutica que contiene oxicodona y naloxona
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
EP2422775A3 (de) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestriermitteluntereinheit und zugehörige Zusammensetzungen und Verfahren
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2514507C (en) 2003-01-28 2012-03-20 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2004091623A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals. Inc. Pharmaceutical formulations containing methylnaltrexone
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
JP5032300B2 (ja) * 2004-03-22 2012-09-26 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物
EP1844792A4 (de) * 2004-12-14 2008-05-21 Shionogi & Co Therapeutisches mittel gegen obstipation
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
WO2006096626A2 (en) 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AU2006274835B2 (en) 2005-07-29 2012-05-24 Abbott Laboratories Gmbh Processes for the manufacture of sterilized pancreatin powder
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
EA200870449A1 (ru) * 2006-04-19 2009-04-28 Джилл П. Смит Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
ES2622576T3 (es) 2006-06-19 2017-07-06 Alpharma Pharmaceuticals Llc Composiciones farmacéuticas
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
MX2009002786A (es) * 2006-09-13 2009-03-30 Procter & Gamble Metodos de tratamiento para colitis ulcerante que utiliza aminosalicilato.
CA2662428A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis
DK2565195T3 (en) 2007-03-29 2015-06-29 Wyeth Llc PERIPHERAL OPIOID RECEPTOR AND ANTAGONISTS AND USES THEREOF
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
EP3263571B2 (de) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Kristallform von (r)-n-methylnaltrexonebromide und verwendungen davon
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2702680A1 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
MX2010011727A (es) * 2008-05-07 2010-11-30 Nektar Therapeutics Administracion oral de antagonistas opioides que actuan perifericamente.
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
LT2384318T (lt) 2008-12-31 2018-02-26 Ardelyx, Inc. Junginiai ir būdai, skirti nhe-medijuoto antiporto slopinimui, gydant sutrikimus, susijusius su skysčių kaupimusi ir druskų pertekliumi, bei virškinamojo trakto sutrikimus
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR20110133602A (ko) 2009-03-10 2011-12-13 유로-셀티큐 에스.에이. 옥시코돈 및 날록손을 포함하는 즉시 방출 제약 조성물
EA201171271A1 (ru) * 2009-04-22 2012-05-30 Фоеме Гмбх Фармацевтическая композиция в форме частиц с опиоидом и антагонистом опиоида
CA2774021A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
KR20130030261A (ko) 2010-05-10 2013-03-26 유로-셀티큐 에스.에이. 활성제-무함유 과립 및 그를 포함하는 정제의 제조
JP5840201B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を負荷した顆粒と追加の活性剤の組合せ
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2013304812B2 (en) 2012-08-21 2016-06-09 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
BR112015004165A2 (pt) * 2012-08-29 2017-07-04 Salix Pharmaceuticals Inc métodos e composições laxantes para o tratamento de constipação e condições e doenças gastrointestinais relacionadas
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
EP3988120A1 (de) 2013-04-12 2022-04-27 Ardelyx, Inc. Nhe3-bindende verbindungen und verfahren zur phosphattransporthemmung
MX2016000810A (es) 2013-07-23 2016-08-05 Euro Celtique Sa Combinacion de oxicodona y naloxona para su uso en el tratamiento de dolor en pacientes que sufren de dolor y una enfermedad que resulta la disbiosis intestinal y/o aumento del riesgo de la translocacion bacteriana intestinal.
CN112716955A (zh) 2013-11-13 2021-04-30 欧洲凯尔特公司 用于治疗疼痛和阿片样物质肠功能障碍综合征的氢吗啡酮和纳洛酮
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
KR20190128626A (ko) 2017-01-09 2019-11-18 알데릭스, 인코포레이티드 Nhe-매개 역수송의 저해제
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2023102491A1 (en) * 2021-12-01 2023-06-08 Invea Therapeutics, Inc. Methods for treating gastrointestinal inflammatory disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381877D1 (de) 1982-03-16 1990-10-18 Univ Rockefeller Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen.
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
IT1188550B (it) * 1986-02-07 1988-01-14 Sclavo Spa Peptide sintetico ad attivita' interleukina 1 umana
US4774230A (en) 1988-03-26 1988-09-27 Ivax Laboratories, Inc. Glucuronic acid derivatives of opioid antagonists
HU218673B (hu) 1993-10-07 2000-10-28 Euroceltique S.A. Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
GB9720797D0 (en) * 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
IT1298575B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
US6277413B1 (en) 1998-07-17 2001-08-21 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
ATE275402T1 (de) 1999-11-01 2004-09-15 John Rhodes Arzneimittel zur behandlung von darmverstopfung und reizkolon

Also Published As

Publication number Publication date
EP1225897B1 (de) 2004-09-08
DE60013630D1 (de) 2004-10-14
CZ299726B6 (cs) 2008-11-05
CA2389650A1 (en) 2001-05-10
EP1225897A2 (de) 2002-07-31
WO2001032180A3 (en) 2001-09-20
JP2003513045A (ja) 2003-04-08
IL149378A (en) 2006-12-31
DK1225897T3 (da) 2005-01-10
AU1044701A (en) 2001-05-14
WO2001032180A2 (en) 2001-05-10
CZ20021536A3 (cs) 2003-02-12
ES2226933T3 (es) 2005-04-01
PT1225897E (pt) 2005-01-31
HK1048595A1 (en) 2003-04-11
US6734188B1 (en) 2004-05-11
DE60013630T2 (de) 2005-09-15
CA2389650C (en) 2008-12-09
IL149378A0 (en) 2002-11-10
AU776567B2 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
ATE275402T1 (de) Arzneimittel zur behandlung von darmverstopfung und reizkolon
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
WO2003097608A3 (en) Opioid and opioid-like compounds and uses thereof
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
NO20020770D0 (no) Anvendelse av monoaminoksidaseinhibitorer for fremstilling av legemidler egnet for behandling av fedme
EP1783126A3 (de) N-Oxide von N-Phenyl-2-Pyrimidinamin Derivaten
ATE446751T1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
CY1109264T1 (el) Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου
EA200870449A1 (ru) Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами
WO2000072837A3 (en) Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
NO20023962L (no) Bruk av IL-18-inhibitorer
EE200200271A (et) Ravimkombinatsioonid ning nende kasutamine
FR2869540B1 (fr) Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers
EE200100378A (et) Tuumorinekroositeguri antagonisti ning seda sisaldava farmatseutilise kompositsiooni kasutamine endometrioosi raviks
ATE465735T1 (de) Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
ATE431142T1 (de) Arzneimittel zur behandlung und vermeidung neurogener schmerzen
ATE296635T1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
RS60604A (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
MY121063A (en) Use of nmda antagonists for treatment of irritable bowel syndrome
ATE293968T1 (de) Verfahren zur vorbeugung gegen und behandlung von unterleibsschmerzen und magen-darmerkrankungen
DE60311822D1 (de) Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen
NO20001894L (no) Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1225897

Country of ref document: EP